Stem Cell Therapy for Heart Failure

What This Article Covers

Stem cell and progenitor cell therapy for heart failure has been studied in human trials for close to two decades, and the picture that has emerged is genuinely encouraging in places — several trials have shown improved heart pumping function, fewer serious cardiac events, or better quality of life in specific patient subgroups — while other results have been flat or inconclusive. No stem cell product is currently FDA-approved to treat heart failure. This page lays out honestly what the science actually shows, where the real promise lies, and who might realistically consider a clinical trial today.

How It's Thought to Work

Heart failure develops when the heart muscle is too weak or stiff to pump blood efficiently, often after a heart attack or from a chronic condition like dilated cardiomyopathy. Because damaged heart muscle cells generally don't regenerate on their own, researchers have spent years testing whether injecting stem or progenitor cells — most often derived from bone marrow or engineered mesenchymal cells — into or near damaged heart tissue could help. The leading theory today isn't that these cells become large numbers of new beating heart muscle cells. Instead, most current evidence points to an indirect mechanism: the injected cells appear to release signaling molecules that calm inflammation, encourage new blood vessel growth, and support the heart's own remaining tissue. A separate and more experimental approach — using lab-grown cardiomyocytes (heart muscle cells) rather than progenitor cells — is being tested in trials such as HEAL-CHF, but that strategy is still in early stages and is distinct from the progenitor-cell trials discussed here.

What the Evidence Shows

The largest and most rigorous trial to date, DREAM-HF, tested Mesoblast's rexlemestrocel-L — mesenchymal precursor cells injected directly into the heart muscle — in 565 patients with chronic heart failure with reduced ejection fraction. The results, published in the Journal of the American College of Cardiology in 2023, are a genuine mixed bag worth sitting with. On the encouraging side, a single injection improved ejection fraction significantly more than a sham procedure at 12 months, and patients saw a striking 58% reduction in heart attacks and strokes — climbing even higher in patients with elevated inflammation markers. That's a real signal that shouldn't be dismissed. But the trial's primary goal — reducing recurrent heart failure hospitalizations — was not met in the overall study population, a sobering reminder that improved heart function on a scan doesn't always translate into fewer hospital stays.

A smaller trial, CardiAMP-HF, tested a patient's own bone marrow cells, delivered via a point-of-care device from BioCardia. Reported in 2024, the study was stopped early after enrolling only 110 of a planned 250 patients, so its findings are described by investigators as preliminary rather than definitive. Still, there's a bright spot here too: patients with elevated NT-proBNP (a heart failure biomarker) showed a notably favorable trend in reduced deaths, transplants, and major cardiac events, prompting a larger, more targeted follow-up trial. Similarly, the CHART-1 trial of cardiopoietic (cardiac-conditioned) mesenchymal cells was neutral overall, but a pre-specified subgroup of patients with more enlarged hearts saw a meaningful, statistically significant improvement in symptoms and quality of life — a promising thread, though the authors themselves caution it needs confirmation in a dedicated trial. One earlier trial, REGENERATE-DCM (2015), stands out as an unusually positive result: in patients with non-ischemic dilated cardiomyopathy, combining bone marrow cells with a growth factor produced a real, statistically significant improvement in ejection fraction that held up at one year, alongside better exercise capacity and symptoms — though this was a modestly sized study that has not yet been replicated at scale.

Taken together, the honest summary is this: cell therapy for heart failure has repeatedly shown it can do something biologically meaningful — better ejection fraction, fewer major events, improved quality of life — but almost always in a subset of patients or on a secondary measure, not consistently across the board on the hardest outcomes like hospitalization and survival.

Who Might Be a Candidate

Because no cell therapy is FDA-approved for heart failure, the only appropriate access point today is a registered clinical trial. People who may want to discuss trial eligibility with a cardiologist include:

• Adults with chronic heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite optimized guideline-directed medical therapy
• Patients with elevated inflammatory markers (such as hsCRP) or elevated NT-proBNP, since several positive signals have concentrated in these subgroups
• People with ischemic heart failure following a prior heart attack, the population targeted by trials like CardiAMP-HF
• People with non-ischemic dilated cardiomyopathy, a population studied in REGENERATE-DCM
• Anyone specifically interested in enrolling in an ongoing, IRB-approved, registered trial (searchable on ClinicalTrials.gov) rather than seeking treatment at a direct-to-consumer stem cell clinic

Bottom Line

Stem and progenitor cell therapy for heart failure is one of the more scientifically credible frontiers in regenerative cardiology — the signals of real benefit in ejection fraction, major adverse cardiac events, and quality of life in specific patient subgroups are genuine and worth watching closely. But it is not an approved treatment, it is not a guaranteed benefit, and the largest trials to date have not consistently hit their primary goals, particularly on hospitalization. Anyone considering this option today should do so only through a legitimate, registered clinical trial with full informed consent, not through unregulated clinics marketing "stem cell treatments" for heart disease — the FDA has repeatedly warned that such offerings are unapproved and unproven.